Before Exelexis’ Cabometyx can pass muster with the FDA in its hopeful neuroendocrine tumors indication next April, it will ...

Two months after Sanofi completed construction in France of its innovative Modulus vaccine and biologics plant—which can be ...

Sac-TMT, also known as SKB264 or MK-2870, represents the first asset in Kelun’s multitarget, multibillion-dollar ADC ...

Once a controversial European depression treatment that never made it to the U.S. | The treatment, which was once a Pfizer ...

On a routine basis in recent years, headlines about layoffs in the biopharma industry have surfaced as companies large and ...

Hovione, a Portuguese CDMO that specializes in spray drying, completed multi-year expansion projects at manufacturing ...

More than three years into a lawsuit accusing competitor Natera of disparaging its cancer blood test, Guardant Health has ...

In 2001, a Time Magazine cover story touted Novartis’ targeted leukemia treatment Gleevec (imatinib) as a new kind of ...

German CDMO Adragos Pharma has been on a growth tear this year, drafting plans to boost capacity in Japan, upgrading a ...

Incyte’s previously disclosed phase 3 win in relapsed or refract | In the phase 3 inMIND study, Monjuvi—added to Bristol ...

Indian drugmaker Lupin is recalling more than 600,000 bottles of the high blood pressure and heart failure drug ramipril due ...

Bristol Myers Squibb has executed another round of layoffs in its ongoing cost-savings push. | Bristol Myers Squibb has ...